Brief: Tracon Pharmaceuticals, 3D Medicines And Jiangsu Alphamab Announce Partnership To Develop Pd-L1 Single-Domain Antibody In Soft Tissue Sarcoma
20/12/2019 12:13
Dec 20 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS, 3D MEDICINES AND JIANGSU ALPHAMAB
ANNOUNCE PARTNERSHIP FOR DEVELOPMENT OF SUBCUTANEOUS PD-L1
SINGLE-DOMAIN ANTIBODY IN SOFT TISSUE SARCOMA
* TRACON PHARMACEUTICALS - INTENDS TO INITIATE A
REGISTRATION
ENABLING STUDY OF ENVAFOLIMAB IN SARCOMA SUBTYPE OF UPS IN 2020
Source text for Eikon: ID:nGNX9YPGRh
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)